放射增敏剂
药代动力学
医学
药理学
血脑屏障
癌症研究
分布(数学)
放射治疗
内科学
中枢神经系统
数学
数学分析
作者
Sneha Rathi,Ju‐Hee Oh,Wenjuan Zhang,Ann C. Mladek,D. Garcia,Zhiyi Xue,Danielle M. Burgenske,Wenqiu Zhang,Jiayan Le,Wei Zhong,Jann N. Sarkaria,William F. Elmquist
标识
DOI:10.1124/jpet.123.001971
摘要
Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Ataxia telangiectasia mutated (ATM) kinase is a key regulator of DSB repair, and ATM inhibitors are being explored as radiosensitizers for various tumors, including primary and metastatic brain tumors. Efficacy of radiosensitizers for brain tumors may be influenced by a lack of effective drug delivery across the blood-brain barrier (BBB). The objective of this study was to evaluate the systemic pharmacokinetics and mechanisms that influence the CNS distribution of WSD0628, a novel and potent ATM inhibitor, in the mouse. Further, we have used these observations to form the basis of predicting effective exposures for clinical application. We observed a greater than dose proportional increase in exposure, likely due to saturation of clearance processes. Our results show that WSD0628 is orally bioavailable and CNS penetrant, with unbound partitioning in CNS (i.e., Kp
科研通智能强力驱动
Strongly Powered by AbleSci AI